437 related articles for article (PubMed ID: 12629092)
41. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients.
Schlumberger M; Hitzel A; Toubert ME; Corone C; Troalen F; Schlageter MH; Claustrat F; Koscielny S; Taieb D; Toubeau M; Bonichon F; Borson-Chazot F; Leenhardt L; Schvartz C; Dejax C; Brenot-Rossi I; Torlontano M; Tenenbaum F; Bardet S; Bussière F; Girard JJ; Morel O; Schneegans O; Schlienger JL; Prost A; So D; Archambeaud F; Ricard M; Benhamou E
J Clin Endocrinol Metab; 2007 Jul; 92(7):2487-95. PubMed ID: 17426102
[TBL] [Abstract][Full Text] [Related]
42. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial.
Schlumberger M; Leboulleux S; Catargi B; Deandreis D; Zerdoud S; Bardet S; Rusu D; Godbert Y; Buffet C; Schvartz C; Vera P; Morel O; Benisvy D; Bournaud C; Toubert ME; Kelly A; Benhamou E; Borget I
Lancet Diabetes Endocrinol; 2018 Aug; 6(8):618-626. PubMed ID: 29807824
[TBL] [Abstract][Full Text] [Related]
43. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma.
Heemstra KA; Liu YY; Stokkel M; Kievit J; Corssmit E; Pereira AM; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2007 Jan; 66(1):58-64. PubMed ID: 17201802
[TBL] [Abstract][Full Text] [Related]
44. Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer.
Toubeau M; Touzery C; Arveux P; Chaplain G; Vaillant G; Berriolo A; Riedinger JM; Boichot C; Cochet A; Brunotte F
J Nucl Med; 2004 Jun; 45(6):988-94. PubMed ID: 15181134
[TBL] [Abstract][Full Text] [Related]
45. Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH.
Pitoia F; Abelleira E; Cross G
Endocrine; 2017 Jan; 55(1):200-208. PubMed ID: 27655291
[TBL] [Abstract][Full Text] [Related]
46. Reoperative lymph node dissection for recurrent papillary thyroid cancer and effect on serum thyroglobulin.
Hughes DT; Laird AM; Miller BS; Gauger PG; Doherty GM
Ann Surg Oncol; 2012 Sep; 19(9):2951-7. PubMed ID: 22526913
[TBL] [Abstract][Full Text] [Related]
47. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin.
Malandrino P; Latina A; Marescalco S; Spadaro A; Regalbuto C; Fulco RA; Scollo C; Vigneri R; Pellegriti G
J Clin Endocrinol Metab; 2011 Jun; 96(6):1703-9. PubMed ID: 21450986
[TBL] [Abstract][Full Text] [Related]
48. Undetectable Thyroglobulin Levels in Poorly Differentiated Thyroid Carcinoma Patients Free of Macroscopic Disease After Initial Treatment: Are They Useful?
Ibrahimpasic T; Ghossein R; Carlson DL; Nixon IJ; Palmer FL; Patel SG; Tuttle RM; Shaha A; Shah JP; Ganly I
Ann Surg Oncol; 2015 Dec; 22(13):4193-7. PubMed ID: 25893415
[TBL] [Abstract][Full Text] [Related]
49. Post-ablative serum thyroglobulin is an independent predictor of recurrence in low-risk differentiated thyroid carcinoma: a 16-year follow-up study.
Pelttari H; Välimäki MJ; Löyttyniemi E; Schalin-Jäntti C
Eur J Endocrinol; 2010 Nov; 163(5):757-63. PubMed ID: 20813788
[TBL] [Abstract][Full Text] [Related]
50. Prevalence, clinical significance and prognostic value of anti-thyroglobulin antibodies in the follow-up of patients with differentiated thyroid carcinoma: a retrospective study.
Pedrazzini L; Baroli A; Lomuscio G; Marzoli L
Minerva Endocrinol; 2009 Sep; 34(3):195-203. PubMed ID: 19859043
[TBL] [Abstract][Full Text] [Related]
51. Impact of pregnancy on serum thyroglobulin and detection of recurrent disease shortly after delivery in thyroid cancer survivors.
Leboeuf R; Emerick LE; Martorella AJ; Tuttle RM
Thyroid; 2007 Jun; 17(6):543-7. PubMed ID: 17614775
[TBL] [Abstract][Full Text] [Related]
52. Conservative management of thyroglobulin-positive, nonlocalizable thyroid carcinoma.
Frank RW; Middleton L; Stack BC; Spencer HJ; Riggs AT; Bodenner DL
Head Neck; 2014 Feb; 36(2):155-7. PubMed ID: 23728951
[TBL] [Abstract][Full Text] [Related]
53. [Comparison of administration of rhTSH with withdrawal of thyroid hormone. Follow-up of patients with differentiated thyroid carcinoma].
Caresia AP; Castell Conesa J; Obiols Alfonso G; Pifarré Montaner P; Negre Busó M; García Alonso C; Galofré Mora P; Mesa Manteca J
Rev Esp Med Nucl; 2006; 25(4):236-41. PubMed ID: 16827986
[TBL] [Abstract][Full Text] [Related]
54. Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study.
Koh JM; Kim ES; Ryu JS; Hong SJ; Kim WB; Shong YK
Clin Endocrinol (Oxf); 2003 Apr; 58(4):421-7. PubMed ID: 12641624
[TBL] [Abstract][Full Text] [Related]
55. Serial post-surgical stimulated and unstimulated highly sensitive thyroglobulin measurements in low- and intermediate-risk papillary thyroid carcinoma patients not receiving radioactive iodine.
Kashat L; Orlov S; Orlov D; Assi J; Salari F; Walfish PG
Endocrine; 2016 Nov; 54(2):460-466. PubMed ID: 27189148
[TBL] [Abstract][Full Text] [Related]
56. Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma.
Muratet JP; Giraud P; Daver A; Minier JF; Gamelin E; Larra F
J Nucl Med; 1997 Sep; 38(9):1362-8. PubMed ID: 9293788
[TBL] [Abstract][Full Text] [Related]
57. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan.
Pineda JD; Lee T; Ain K; Reynolds JC; Robbins J
J Clin Endocrinol Metab; 1995 May; 80(5):1488-92. PubMed ID: 7744991
[TBL] [Abstract][Full Text] [Related]
58. [Follow-up of high-risk patients with differentiated thyroid cancer without persistent disease after initial therapy].
do Rosário PW; Borges MA; Alves MF; Purisch S; Padrão EL; Rezende LL; Barroso AL
Arq Bras Endocrinol Metabol; 2006 Oct; 50(5):909-13. PubMed ID: 17160215
[TBL] [Abstract][Full Text] [Related]
59. [Use of serum thyroglobulin determination in the follow-up of differentiated carcinomas of the thyroid].
Secades Ariz I; Pérez Piqueras JL; Labanda Tejedor P; Cordero Peinado J
An Med Interna; 1988 Sep; 5(9):439-43. PubMed ID: 2856622
[No Abstract] [Full Text] [Related]
60. Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma.
Franceschi M; Kusić Z; Franceschi D; Lukinac L; Roncević S
J Nucl Med; 1996 Mar; 37(3):446-51. PubMed ID: 8772642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
